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Cancer registration in Northern Africa is still limited and, until
now, there have been no population-based data available for
Libya. In this paper, we present the ﬁrst data collected and ana-
lyzed by the Benghazi Cancer Registry. Registration was carried
out by active data collection; the registry staff routinely visited all
hospitals and pathological laboratories in eastern Libya (1.6 mil-
lion inhabitants) and collected information from all death regis-
tration ofﬁces. A huge archive of prevalent cases was established
before the 2003 data were collected. A total of 997 cases of pri-
mary cancers were registered among residents in 2003. The world
age-standardized incidence rate for all sites combined (except non-
melanoma skin) was 118 per 100,000 for men and 95 per 100,000
for women. The most frequently diagnosed malignancies in males
were lung cancer (19%) and colorectal cancer (10%), followed by
cancers of the head and neck (9%) and bladder (9%). Among
females, they were breast cancer (26%), cancer of the colon and
rectum (9%), uterus (7%) and non-Hodgkin lymphoma (5%).
Our study provides data on cancer incidence in eastern Libya,
and conﬁrms that cancer incidence is much lower than in western
countries. Moreover, observed patterns indicate that the incidence
of many cancers, including those of the lung, breast, colon, rectum
and bladder is quite different from previous estimates based on
the data available from the neighboring countries.
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Cancer will become an increasingly important health problem
in developing countries in the coming decades. Growing and age-
ing populations, increasing tobacco consumption and exposure to
other known risk factors (e.g., industrialization and westernization
of diet and lifestyle) will all contribute to dramatically increase
the number of new cancer cases, especially in African countries.1,2
The establishment of several new cancer registries in Africa in the
last 15 years3–8 will provide more accurate statistics and help to
improve both the monitoring of cancer trends over time and our
understanding of this growing epidemic. Although cancer registra-
tion activity in Africa is growing rapidly, until now no cancer inci-
dence data have been available for a deﬁned population within
Libya.7,9–11 In this paper, we report for the ﬁrst time the statistics
on cancer incidence from the population-based Benghazi Cancer
Registry (BCR), which was established in 2002 under the auspices
of the National Research Center and located in Garyounis Uni-
versity, in eastern Libya.
Material and methods
The BCR covers a wide area of northeastern Libya, on the
Mediterranean Sea coast (Fig. 1). The total population, according
to 2003 estimates, is 1,632,051 (approximately 28% of the total
Libyan population), with a high proportion of children (age 0–14:
35%) and young adults (age 15–29: 32%), while people older than
65 years only account for less than 5% (Fig. 2). The city of
Benghazi (660,147 estimated population) is the major center of
the region.
Cases were found by active searching in all hospitals in which
cancer may be diagnosed. The Department of Pathology of
Garyounis University, located in the city of Benghazi, is the most
important source of information because it provides histopathol-
ogy and cytology services for the whole of eastern Libya. All other
public and private pathology laboratories were also periodically
visited. Death certiﬁcates were actively investigated and followed
up to obtain additional information related to the exact date and
site of diagnosis.
Data are provided for the latest complete registration year
(2003). Registrations included all malignant tumours; nonmela-
noma skin cancer was excluded from the statistics if not other-
wise indicated. Registrations are considered microscopically
veriﬁed (MV) where diagnosis is based on a malignant histologi-
cal or cytological reports.
Cases were classiﬁed according to the third edition of the Inter-
national Classiﬁcation of Diseases for Oncology.12 The staff of
the Modena Cancer Registry (MCR), Italy, contributed to the train-
ing of registrars in coding techniques and in software use. Coding
practices (including basis and the date of diagnosis) were deﬁned
according to the current international guidelines.12–14 Age stand-
ardization of incidence rates was carried out by the direct method,
using the world standard population.15 The registry used statistical
and data entry software developed by the MCR. It includes a vari-
ety of methods for checking the validity of the data, based on the
IARC/IACR check programs.16
Results
A total of 997 cases diagnosed in 2003 were registered by the
BCR, of which 544 were males (54.6%) and 453 females (45.4%).
Excluding nonmelanoma skin cancers, the total number of cases
was 978 (529 males and 449 females). The mean age at time of
diagnosis was 57 years for males and 49 years for females. The
age distribution and the age-speciﬁc incidence rates are presented
in Figure 3.
The most frequently reported malignancies in males were lung
cancer (19% of all cases, excluding skin cancers), colorectal can-
cer (10%), cancer of the head and neck (9%), bladder (9%) and
prostate (8%). The most frequently reported malignancies among
females were breast cancer (26% of all cases), followed by cancers
of the colon and rectum (9%), corpus uteri (7%), non-Hodgkin
lymphomas (5%) and cervix uteri (5%) (Table I).
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FIGURE 1 – Area covered by the BCR.
FIGURE 2 – Resident population, 2003, according to sex and age (years).
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According to morphology, ductal inﬁltrating carcinoma was the
most common histological type (54%) of all female breast malig-
nancies, while lobular carcinomas accounted for 11%.
Adenocarcinoma was the most common type of lung cancer,
accounting for 34% of all MV lung neoplasms, followed by squa-
mous cell carcinoma (29%), small-cell carcinoma (14%) and
large-cell carcinoma (9%).
Transitional cell carcinoma represented 72% of all bladder can-
cers, followed by adenocarcinoma of unspeciﬁed type (17%).
Only 4% of bladder cancers were of the squamous cell type.
The most valid basis of diagnosis at each cancer site, sorted by
gender, is reported in Table II: 79% of all cancers were veriﬁed by
microscopy, and 9.9% were documented only by a death certiﬁ-
cate. A comparison of age-standardized rates (ASR) in Benghazi
with those of other African areas7,8 and with the estimated cancer
incidence for Libya provided by the Globocan 2002 database is
presented in Table III.17
Discussion
The results presented here are the ﬁrst from a population-based
cancer registry in Libya, although several clinical and hospital-
based series have been published in the past.9–11
As expected, the overall cancer incidence rate in Benghazi
is lower than that in more developed countries, but it is higher than
the rate estimated for Libya, according to the Globocan 2002
database. The main differences are the higher incidence in Ben-
ghazi of lung and prostate cancer in males, and of colon-rectal
cancer in both sexes, while bladder and uterine cervical cancer
incidence seems to be much lower than expected by Globocan
2002 estimations.
The high rate of lung cancer is similar to the average of rates
reported in North African cancer registries,7 mainly because of the
well-established smoking habit within the Libyan population.
According to the latest statistics for Libya, the annual per capita
consumption of cigarettes in Libya in 1980 was extremely high
(3,950) when compared, for example, with that in Algeria (1,499)
and Tunisia (1,543), but also with Italy (2,351), the United States
(3,544) and Japan (3,450).18 Because of the long latency of the
disease and to the lack of effective smoking control programs, it is
reasonable to expect an increase in lung cancer incidence in the
Benghazi area. The proportion of adenocarcinoma (34%) in
Benghazi is slightly higher than Garbiah, Egypt (30%), Jordan
(28%) and lower than United States (37%).8 The monitoring of
these results as well as the analysis of time trend will probably
explain the real signiﬁcance of these differences.
Colorectal cancer is relatively frequent in Benghazi. This is in
contrast with the Globocan 2002 estimates. Moreover, the inci-
dence of colorectal cancer in Benghazi is closer to that reported in
other North African cancer registries. The higher incidence rates
are probably due to dietary factors, variations in economic status
and the diffusion of endoscopic procedures, especially in urban
areas of eastern Libya.
As expected, breast cancer was the most common malignancy
in women, accounting for more than 25% of all cancer in females,
and the ductal subtype was the most frequent morphology among
the microscopically conﬁrmed cases. The young age structure of
FIGURE 3 – Age distribution (%) and age-speciﬁc incidence rates for all cancers combined.
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the Libyan population and the rather smooth age-incidence curve
mean that the average age at diagnosis, as reported in many clini-
cal series for other African countries,7 is lower than in European
populations. Based on these data, it is unclear whether mass-
screening programs would be feasible in a country with such rela-
tively low incidence. We think that more studies, such as research
on the role of genetic factors among African women, should
be done for a better understanding of the best way to ﬁght breast
cancer in Libya.
The incidence of bladder cancer in Benghazi is lower than
expected. The remarkable difference from the predicted cancer
incidence for Libya reported by the Globocan 2002 database,
especially among males, is probably due to the fact that the
Globocan 2002 calculation is based on the average of neighboring
countries, including Egypt, where the estimated17 incidence rate
in males is the highest in the world (ASR: 37 per 100,000),
although both the Algerian and Tunisian cancer registries reported
much lower incidence rates among males (Algiers: 11 per 100,000;
Tunis: 12 per 100,000). Apart from smoking attitude, no other
risk factor has been identiﬁed within the Benghazi area. The re-
latively limited occurrence of schistosomiasis was conﬁrmed by
the low incidence of squamous cell tumors (4% of all MV
bladder cancers) when compared with that observed in the area
covered by the Garbiah Cancer Registry (25%), in Egypt.8
Our data conﬁrm that this region’s demographic variables, such
as marital status, ethnicity, religion and social status, differ
strongly from those of southern Africa. Consequently, fewer risk
factors may be related to cancers such as Kaposi sarcoma and
cancer of the cervix uteri.
The level of MV cases (79%) is much higher than in other Afri-
can cancer registries,7 but lower than the averages of Algeria
(88%) and Tunisia (90%), while little difference was found be-
tween Benghazi and Garbiah (82%).8 Unfortunately, a large pro-
portion of cancer cases are still reported by death certiﬁcate only
(DCO) (10%) and 11% of cases had only clinic-based conﬁrma-
tion. Although these rates demonstrate that the degree of depend-
ence upon histopathology for BCR is very limited, we believe that
the quality of the BCR data may be enhanced in the near future.
However, the percentages of both MV and DCO cases are compa-
rable with many other cancer registries located in Africa, Asia,
and South America.15
Cancer registration has proved to be difﬁcult in Benghazi.
Some problems are common to most African cancer registries.
These include uncertainty regarding population sizes, difﬁculty
in deﬁning the place of residence and the poor quality of
death certiﬁcate notiﬁcations, and may limit the accuracy of
reports from these areas. It has been noticed13 that another
factor that may affect initial reports from population-based
TABLE I – NUMBER OF NEW CASES BY AGE (YEARS), SEX AND SITE
Site
0–14 15–24 25–34 35–44 45–54 55–64 651 Total
M F M F M F M F M F M F M F M F
Lip 0 0 0 0 0 0 0 0 0 0 1 0 1 1 2 1
Tongue 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1
Mouth 0 0 0 0 0 0 0 0 0 0 1 2 3 0 4 2
Salivary gland 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1
Oropharynx 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1
Nasopharynx 2 0 0 0 0 1 4 1 2 1 2 1 1 0 11 4
Hypopharynx 0 0 0 0 0 0 0 0 0 0 0 0 2 0 2 0
Esophagus 0 0 0 0 0 0 1 0 0 0 2 0 3 0 6 0
Stomach 0 0 0 0 2 1 4 3 6 5 3 2 6 3 21 14
Colon 0 0 3 1 0 2 2 6 1 8 11 5 11 9 28 31
Rectum 0 0 0 0 2 1 4 2 5 5 7 2 6 0 24 10
Liver 0 0 0 0 0 0 0 0 2 0 1 7 10 5 13 12
Gallbladder, etc. 0 0 0 0 0 0 1 2 0 2 3 4 3 6 7 14
Pancreas 0 0 0 0 0 0 2 2 4 0 3 3 8 2 17 7
Larynx 0 0 0 0 1 0 1 0 4 0 6 1 14 0 26 1
Lung 0 0 0 0 0 0 7 0 16 3 29 2 49 2 101 7
Bone 2 2 1 1 0 1 0 2 0 1 0 0 0 1 3 8
Skin melanoma 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0
Other skin 0 0 0 0 1 0 3 1 1 0 2 0 8 3 15 4
Mesothelioma 0 0 0 0 0 0 0 0 1 0 0 0 1 0 2 0
Kaposi sarcoma 0 0 0 0 1 0 0 0 0 0 0 0 2 0 3 0
Soft tissue 2 3 0 1 5 2 1 0 3 3 1 0 5 2 17 11
Breast 0 0 0 0 0 19 0 34 0 33 1 19 1 11 2 116
Prostate 0 – 0 – 0 – 2 – 0 – 10 – 33 – 45 –
Testis 0 – 1 – 0 – 0 – 1 – 0 – 0 – 2 –
Cervix uteri – 0 – 0 – 0 – 4 – 11 – 6 – 2 – 23
Uterus – 0 – 0 – 0 – 1 – 7 – 17 – 5 – 30
Ovary – 1 – 3 – 4 – 6 – 3 – 2 – 4 – 23
Kidney, etc. 3 1 0 0 0 1 0 2 2 3 4 2 8 3 17 12
Bladder 0 0 0 0 1 0 2 2 8 0 11 1 27 3 49 6
Brain and CNS 1 6 5 1 3 2 1 3 4 0 9 0 5 2 28 14
Thyroid 1 0 0 1 1 5 0 1 0 6 0 1 0 3 2 17
Hodgkin disease 1 0 6 3 1 4 2 1 1 1 0 0 0 0 11 9
Non-Hodgkin lymphoma 4 3 1 4 5 1 3 0 4 6 5 4 6 7 28 25
Myeloma 0 0 0 0 0 0 0 1 1 0 3 0 2 3 6 4
Acute lymphoid leukemia 2 2 3 1 1 0 0 0 0 0 0 0 2 0 8 3
Chronic lymphoid leukemia 0 0 0 0 0 0 1 1 0 1 0 0 1 2 2 4
Acute myeloid leukemia 1 0 3 4 0 1 1 0 0 1 5 0 1 1 11 7
Chronic myeloid leukemia 0 0 0 0 0 2 0 1 0 0 0 2 0 1 0 6
Other and unspeciﬁed 3 0 1 0 1 2 4 3 4 4 6 3 9 13 28 25
Total (including skin) 22 18 24 20 25 49 46 79 71 105 128 87 228 95 544 453
Total (excluding skin) 22 18 24 20 24 49 43 78 70 105 126 87 220 92 529 449
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cancer registries is overestimation due to the misclassiﬁcation
of prevalent cases. At the time this paper was published, our
archives contained a signiﬁcant number of prevalent cases,
mostly diagnosed in 1999–2002. In conclusion, although this
report includes only 1 year of data, we believe that the ﬁgures
presented here provide a reasonably accurate description of
cancer incidence in the Benghazi area and can contribute to a
better understanding of cancer incidence patterns along the
southern coast of the Mediterranean Sea.
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TABLE II – PERCENTAGE OF CASES WITH MICROSCOPICAL VERIFICATION (MV)
AND DEATH CERTIFICATE ONLY (DCO) REGISTRATIONS
Site MV DCO
Oral cavity 100 0
Nasopharynx 93.33 7.26
Hypopharynx 100 0
Esophagus 66.67 33.33
Stomach 80 11.43
Colon 81.36 10.17
Rectum 94.12 2.94
Liver 20.38 28
Gallbladder, etc. 52.38 4.76
Pancreas 33.33 20.84
Larynx 77.77 18.52
Lung 52.77 18.52
Bone 100 0
Skin melanoma 100 0
Other skin 100 0
Mesothelioma 100 0
Kaposi sarcoma 100 0
Soft tissue 96.43 3.57
Breast 94.32 2.54
Prostate 84.44 6.67
Testis 100 0
Cervix uteri 86.96 13.4
Uterus 93.33 6.67
Ovary 86.96 0
Kidney, etc. 82.76 6.89
Bladder 94.55 5.45
Brain and CNS 59.52 26.19
Thyroid 94.74 0
Hodgkin disease 100 0
Non-Hodgkin lymphoma 94.35 3.77
Myeloma 70 20
Leukemias 97.56 2.44
Other and unspeciﬁed 54.7 22.6
Total (including skin) 79.33 9.73
Total (excluding skin) 79.04 9.92
TABLE III – WORLD ASR IN BENGHAZI COMPARED TO OTHER AFRICAN COUNTRIES AND TO THOSE EXPECTED
FOR LIBYA ACCORDING TO GLOBOCAN 2002 ESTIMATES
Site
Benghazi CR
(2003)
Libya (est.),
Globocan (2002)17
Algiers, Algeria
(1993–1997)7
Tunis, Tunisia
(1994)7
Garbiah, Egypt
(1999–2001)8
Males Females Males Females Males Females Males Females Males Females
Nasopharynx 1.9 0.8 2.2 0.9 2.7 1.2 3.7 1.8 1.4 0.5
Esophagus 1.5 0 2.4 1 0.9 0.5 1.2 1 1.7 1
Stomach 4.4 3.4 4.1 1.5 5.6 3.7 6.1 3.5 3.6 2.2
Colon and rectum 11.6 8.8 4.9 2.5 7.1 6.1 6.2 7 6.9 5.1
Liver 3.3 3.1 4.8 1.6 0.9 0.9 2.9 1.8 20.1 5.2
Gallbladder, etc. 1.6 3.6 n.a. n.a. 1.5 5.3 1.7 4.4 1.2 0.8
Pancreas 4.4 1.6 1.5 0.5 1.2 0.9 2.4 1.7 3.7 2.5
Larynx 6.1 0.3 3.7 0.5 4.3 0.3 6.3 0.3 4.2 0.3
Lung 24.8 2 10.4 1.5 17.2 1.9 26.6 2.3 11.9 3.7
Breast – 22.9 – 17.4 – 21.2 – 24.1 – 49.6
Prostate 11.4 – 5.6 – 5.4 – 7.9 – 7.5 –
Cervix uteri – 5.3 – 8.2 – 12.6 – 6.1 – 2.7
Uterus – 8 – 1.6 – 3.2 – 2.4 – 3.5
Ovary – 4 – 1.9 – 1 – 2.9 – 5.4
Kidney, etc. 3.9 2.8 1.8 0.9 1.4 1.5 1.7 1.3 3.2 1.7
Bladder 11.7 1.3 22.4 2.7 10.8 2.3 12.3 1 27.5 6.3
Brain and CNS 5.3 2.1 2.1 1.1 2.7 1.4 2.6 1.3 3.8 3.5
Hodgkin disease 1.2 1 1.3 0.4 0.5 0.5 1.6 0.9 2.9 1.4
Non-Hodgkin lymphoma 5.3 5.4 4.2 1.8 3.6 2.4 5.4 3.5 17.1 11.3
Myeloma 1.6 1.9 0.7 0.4 0.7 0.6 1.8 1.6 1.4 0.6
Leukemias 4.8 3.6 4 2.2 2.4 1.5 4.3 4.4 6.7 5.3
Total (excluding skin) 117.6 95 99.3 84.7 86 85.9 113.9 89.1 152.6 135
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